

MEDIA RELEASE: IQnovate Eyes Booming Biopharmaceutical Market

SYDNEY, Australia, May 23, 2013 -- IQnovate Ltd (NSX: IQN, OTC: IQNDY)

IQnovate is pleased to announce that following last week's quotation clearance of its level 1 American Depositary Receipts, the Company has now been featured in the media in the United States of America (USA).

The media coverage can be viewed from the following link:

<http://investmentunderground.com/6863/featured/ignovate-eyes-booming-biopharmaceutical-market/>

Con Tsigounis, Investor Relations. Telephone: +61 (2) 8239-5400

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with IQnovate's business can be found in its periodic filings with the National Stock Exchange of Australia.

SOURCE IQnovate Limited

IQnovate Ltd is a life science organisation, providing intellectual property asset management services and scientific advice to the global Biopharmaceutical industry.

Whether the asset is a pharmaceutical, medical device, technology platform or a compound in development, IQNovate will effectively manage your asset through its complete life cycle, from clinical trials right through to maturity.

IQNovate clients are pharmaceutical, biotechnology, medical device companies as well as financial institutions, academic and government organisations.